Lv1
50 积分 2024-10-03 加入
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
MA09.07 Body Roundness Index and Polygenic Risk Score Improve Lung Cancer Risk Prediction Over BMI: Prospective Analyses in the UK Biobank
1个月前
已关闭
MA10.09 Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial
2个月前
已关闭
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
2个月前
已完结
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
2个月前
已关闭
MA10.09 Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial
3个月前
已关闭
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
3个月前
已完结
Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer
3个月前
已完结
Small cell lung cancer
5个月前
已完结
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
6个月前
已完结
皖公网安备34019202002308
